<DOC>
	<DOCNO>NCT02280590</DOCNO>
	<brief_summary>Comparison efficacy safety Cresnon® Crestor® patient hyperlipidemia - 8-week , active-controlled , open-label , randomize , parallelgroup , fixed-dose , noninferiority , multicenter , phase 4 design</brief_summary>
	<brief_title>Comparison Efficacy Safety Cresnon® Crestor® Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age ≥ 20 Persons reach LDLC target level accordance treatment guideline dyslipidemia release Korean Society Lipidology Atherosclerosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>